MEXATE-AQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mexate-aq, and when can generic versions of Mexate-aq launch?
Mexate-aq is a drug marketed by Bristol Myers and Bristol Myers Squibb and is included in two NDAs.
The generic ingredient in MEXATE-AQ is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mexate-aq
A generic version of MEXATE-AQ was approved as methotrexate sodium by HIKMA on September 16th, 1986.
Summary for MEXATE-AQ
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 137 |
| Clinical Trials: | 129 |
| Patent Applications: | 4,342 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MEXATE-AQ at DailyMed |
Recent Clinical Trials for MEXATE-AQ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Children's Oncology Group | Phase 2/Phase 3 |
| City of Hope Medical Center | Phase 1 |
| AbbVie | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for MEXATE-AQ
US Patents and Regulatory Information for MEXATE-AQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers | MEXATE-AQ | methotrexate sodium | INJECTABLE;INJECTION | 088760-001 | Feb 14, 1985 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bristol Myers Squibb | MEXATE-AQ PRESERVED | methotrexate sodium | INJECTABLE;INJECTION | 089887-001 | Apr 14, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
